Wenya Pei , Boyu Jiao , Zexiong Chen , Jingchun Zeng , Yancheng Fu , Zhanmou Liang , Baoguo Sun , Jingwen Ruan , Shijun Zhang
{"title":"The knowledge mapping of traditional Chinese medicine for hepatocellular carcinoma: A bibliometric study","authors":"Wenya Pei , Boyu Jiao , Zexiong Chen , Jingchun Zeng , Yancheng Fu , Zhanmou Liang , Baoguo Sun , Jingwen Ruan , Shijun Zhang","doi":"10.1016/j.prmcm.2025.100581","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Traditional Chinese medicine is widely used as adjuvant therapy for hepatocellular carcinoma (HCC), but no relevant bibliometric study has comprehensively analyzed the available data.</div></div><div><h3>Methods</h3><div>To summarize the research landscape of traditional Chinese medicine (TCM) in relation to HCC over the past decade, publications on TCM and HCC from 2013 to 2023 were collected and analyzed using CiteSpace software.</div></div><div><h3>Results</h3><div>A total of 1,160 articles on TCM for HCC were included in the bibliometric analysis, with the most productive countries and institutions located in the Asia region. The analysis indicated that traditional Chinese medicine may enhance immunity and regulate the local tumor microenvironment through mechanisms involving DNA damage, cell cycle arrest, and apoptosis by signaling pathways.</div></div><div><h3>Discussion</h3><div>This study provides insights into the trends of traditional Chinese medicine for hepatocellular carcinoma, which may inform clinical practice and identify potential targets for further research. However, high-quality evidence-based research and rigorous mechanistic studies should be prioritized to explore new anticancer approaches.</div></div>","PeriodicalId":101013,"journal":{"name":"Pharmacological Research - Modern Chinese Medicine","volume":"14 ","pages":"Article 100581"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Research - Modern Chinese Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667142525000107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Traditional Chinese medicine is widely used as adjuvant therapy for hepatocellular carcinoma (HCC), but no relevant bibliometric study has comprehensively analyzed the available data.
Methods
To summarize the research landscape of traditional Chinese medicine (TCM) in relation to HCC over the past decade, publications on TCM and HCC from 2013 to 2023 were collected and analyzed using CiteSpace software.
Results
A total of 1,160 articles on TCM for HCC were included in the bibliometric analysis, with the most productive countries and institutions located in the Asia region. The analysis indicated that traditional Chinese medicine may enhance immunity and regulate the local tumor microenvironment through mechanisms involving DNA damage, cell cycle arrest, and apoptosis by signaling pathways.
Discussion
This study provides insights into the trends of traditional Chinese medicine for hepatocellular carcinoma, which may inform clinical practice and identify potential targets for further research. However, high-quality evidence-based research and rigorous mechanistic studies should be prioritized to explore new anticancer approaches.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
